Advertisement

Der Internist

, Volume 51, Issue 3, pp 402–409 | Cite as

Möglichkeiten und Grenzen der onkologischen Chemotherapie bei alten Patienten

  • U. Wedding
Arzneimitteltherapie

Zusammenfassung

Das chronologische Alter eines Patienten ist keine Grenze für die Durchführung einer Chemotherapie, denn auch alte Menschen können von einer Chemotherapie profitieren. Ein diagnostischer und therapeutischer Nihilismus allein aufgrund des Alters eines Patienten ist daher nicht gerechtfertigt. Allerdings stehen nur wenige Daten mit hohem Evidenzlevel zur Behandlung alter Patienten mit Krebserkrankungen zur Verfügung. Das chronologische Alter allein ist kein hinreichendes Kriterium für die Beschreibung des gesundheitlichen Zustands eines Patienten. Ein systematisches geriatrisches Assessment bildet die individuellen Defizite und Ressourcen sehr viel besser ab. Die hier abgebildeten Einschränkungen sind Risikofaktoren für das Auftreten von Toxizitäten und für einen geringeren Behandlungsvorteil im Rahmen der Chemotherapie. Die zur Verfügung stehenden Daten sprechen dafür, dass es sowohl eine Unter- als auch eine Übertherapie gibt.

Schlüsselwörter

Chemotherapie Alte Patienten Komorbiditäten Funktioneller Status Geriatrisches Assessment 

Chances and limitations of chemotherapy in elderly patients

Abstract

The chronological age of a patient should not be a barrier to apply chemotherapy. Elderly patients can benefit from chemotherapy. Chronological age should not be a reason for diagnostic or therapeutic nihilism, as the age of a patient poorly characterizes their health situation. Data with high level of evidence on treatment of elderly patients with cancer are limited. A comprehensive geriatric assessment (CGA) describes the individual deficits and resources of a patient much better. Limitations in CGA are risk factors for increased toxicity and decreased treatment benefit. The currently available data demonstrate under- and over-treatment in elderly patients with cancer.

Keywords

Chemotherapy Elderly Co-morbidity Functional status Geriatric assessment 

Notes

Interessenkonflikt

Keine Angaben.

Literatur

  1. 1.
    Albert US (Hrsg) (2008) Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Zuckschwerdt, München Wien New YorkGoogle Scholar
  2. 2.
    André T, Boni C, Mounedji-Boudiaf L et al.; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators (2004) Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343–2351CrossRefPubMedGoogle Scholar
  3. 3.
    Bergh J, Holmquist M (2001) Who should not receive adjuvant chemotherapy? International databases. J Natl Cancer Inst Monogr 30: 103–108PubMedGoogle Scholar
  4. 4.
    Cunningham D, Allum WH, Stenning SP et al.; MAGIC Trial Participants (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11–20CrossRefPubMedGoogle Scholar
  5. 5.
    Early Breast Cancer Trialists‘ Collaborative Group, Clarke M, Coates AS, Darby SC, Davies C et al. (2008) Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371: 29–40CrossRefGoogle Scholar
  6. 6.
    Edwards BK, Howe HL, Ries LA et al. (2002) Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94: 2766–2792CrossRefPubMedGoogle Scholar
  7. 7.
    Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91: 66–72CrossRefGoogle Scholar
  8. 8.
    Elkin EB, Hurria A, Mitra N et al. (2006) Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 24: 2757–2764CrossRefPubMedGoogle Scholar
  9. 9.
    Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25: 1824–1831CrossRefPubMedGoogle Scholar
  10. 10.
    Friedrich C, Kolb G, Wedding U, Pientka L; Interdisziplinäre Arbeitsgruppe der DGHO/DGG (2003) Comprehensive geriatric assessment in the elderly cancer patient. Onkologie 26: 355–360CrossRefPubMedGoogle Scholar
  11. 11.
    Früh M, Rolland E, Pignon JP et al. (2008) Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 26: 3573–3581CrossRefPubMedGoogle Scholar
  12. 12.
    Giordano SH, Duan Z, Kuo YF et al. (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24: 2750–2756CrossRefPubMedGoogle Scholar
  13. 13.
    Goldhirsch A, Coates AS, Gelber RD et al.; St Gallen Expert Panel Members (2006) First – select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 17: 1772–1776CrossRefPubMedGoogle Scholar
  14. 14.
    Harter P, du Bois A, Schade-Brittinger C et al. (2005) Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol 16: 1801–1805CrossRefPubMedGoogle Scholar
  15. 15.
    Honecker F, Wedding U, Rettig K et al. (2009) Use of the comprehensive geriatric assessment (CGA) in elderly patients (pts) with solid tumors to predict mortality. ASCO abstract. J Clin Oncol 27: 9549CrossRefGoogle Scholar
  16. 16.
    Hutchins LF, Unger JM, Crowley JJ et al. (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341: 2061–2067CrossRefPubMedGoogle Scholar
  17. 17.
    Keating NL, Landrum MB, Klabunde CN et al. (2008) Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 26: 2532–2537CrossRefPubMedGoogle Scholar
  18. 18.
    Kemeny MM, Peterson BL, Kornblith AB et al. (2003) Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21: 2268–2275CrossRefPubMedGoogle Scholar
  19. 19.
    Köhne CH, Folprecht G, Goldberg RM et al. (2008) Chemotherapy in elderly patients with colorectal cancer. Oncologist 13: 390–402CrossRefPubMedGoogle Scholar
  20. 20.
    Kudoh S, Takeda K, Nakagawa K et al. (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24: 3657–3663CrossRefPubMedGoogle Scholar
  21. 21.
    Lewis JH, Kilgore ML, Goldman DP et al. (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21: 1383–1389CrossRefPubMedGoogle Scholar
  22. 22.
    McCleary NA, Meyerhardt J, Green E et al (2009) Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. J Clin Oncol 27: abstr 4010Google Scholar
  23. 23.
    Muss HB, Berry DA, Cirrincione CT et al.; CALGB Investigators.(2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360: 2055–2065CrossRefPubMedGoogle Scholar
  24. 24.
    Pallis AG, Gridelli C, van Meerbeeck JP et al. (2009) EORTC Elderly Task Force and Lung Cancer Group and International Society For Geriatric Oncology (SIOG) experts‘ opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol [Epub ahead of print]Google Scholar
  25. 25.
    Pignon JP, Tribodet H, Scagliotti GV et al.; LACE Collaborative Group (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 26: 3552–3559CrossRefPubMedGoogle Scholar
  26. 26.
    Sargent D, Sobrero A, Grothey A et al. (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27: 872–877CrossRefPubMedGoogle Scholar
  27. 27.
    Sargent DJ, Goldberg RM, Jacobson SD et al. (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: 1091–1097CrossRefPubMedGoogle Scholar
  28. 28.
    Sargent DJ, Wieand HS, Haller DG et al. (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23: 8664–8670CrossRefPubMedGoogle Scholar
  29. 29.
    Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96: 1311–1321PubMedCrossRefGoogle Scholar
  30. 30.
    Sundararajan V, Mitra N, Jacobson JS et al. (2002) Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136: 349–357PubMedGoogle Scholar
  31. 31.
    Wagner AD, Wedding U (2009) Advances in the pharmacological treatment of gastro-oesophageal cancer. Drugs & Aging 26: 627–646Google Scholar
  32. 32.
    Wedding U, Honecker F, Bokemeyer C et al. (2007) Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 14: 44–56PubMedGoogle Scholar
  33. 33.
    Wedding U, Honecker F, Rettig K et al (2008) Comprehensive geriatric assessment (CGA) in elderly patients with hematological neoplasia: CGA and not age predicts mortality – results from the IN-GHO® registry. ASH abstract. Blood 112: 474Google Scholar
  34. 34.
    Wedding U, Honecker F, Pienkta L, Höffken K (2007) Klinische Studien und Patientenregister für alte Patienten mit Krebserkrankungen. Onkologe 13: 783–791CrossRefGoogle Scholar
  35. 35.
    Wimberger P, Lehmann N, Kimmig R et al.; AGO-OVAR (2006) Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 100: 300–307CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2010

Authors and Affiliations

  1. 1.Klinik für Innere Medizin II, Abteilung PalliativmedizinUniversitätsklinikum JenaJenaDeutschland

Personalised recommendations